MAINTENANCE OLAPARIB RECHALLENGE IN PATIENTS WITH OVARIAN CANCER PREVIOUSLY TREATED WITH A PARP INHIBITOR: PATIENTREPORTED OUTCOMES FROM THE PHASE IIIB OREO/ENGOT-OV38 TRIAL

被引：0

作者：

Redondo, Andres ^{[1
,2
]}

Follana, Philippe ^{[3
,4
]}

Scambia, Giovanni ^{[5
,6
]}

Asselain, Bernard ^{[7
]}

Marme, Frederik ^{[8
,9
]}

Mirza, Mansoor ^{[10
,11
]}

Laudani, Maria Elena ^{[12
]}

Madry, Radoslaw ^{[13
,14
]}

Glasspool, Rosalind ^{[15
,16
,17
]}

You, Benoit ^{[18
,19
]}

Jesus Rubio-Perez, Maria ^{[20
,21
]}

Zamagni, Claudio ^{[22
,23
]}

El-Balat, Ahmed ^{[24
,25
]}

Hardy-Bessard, Anne Claire ^{[26
,27
]}

Oaknin, Ana ^{[28
,29
]}

Ronzino, Graziana ^{[30
,31
]}

Shaw, Bob ^{[32
]}

Nakamura, Hitomi ^{[33
]}

Berton, Dominique ^{[34
]}

Pujade-Lauraine, Eric ^{[35
]}

机构：

[1] La Paz Univ Hosp, Madrid, Spain

[2] GEICO, Dept Med, Madrid, Spain

[3] Ctr Antoine Lacassagne, Nice, France

[4] GINECO, Dept Med Oncol, Nice, France

[5] Fdn Policlin Univ A Gemelli, IRCCS, UOC Ginecol Oncol, Rome, Italy

[6] MITO, Dipartimento Salute Donna & Bambino & Salute Pubb, Rome, Italy

[7] ARCAGY GINECO, Dept Biostat, Paris, France

[8] Heidelberg Univ, Univ Hosp Mannheim, Mannheim, Germany

[9] AGO, Med Fac Mannheim, Mannheim, Germany

[10] Rigshosp, Copenhagen, Denmark

[11] NSGO, Dept Canc Treatment, Copenhagen, Denmark

[12] Univ Turin, St Anna Hosp, Dept Gynecol & Obstet, Turin, Italy

[13] Poznan Univ Med Sci, Poznan, Poland

[14] PGOG, Dept Gynecol Oncol, Poznan, Poland

[15] Univ Glasgow, Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland

[16] Univ Glasgow, Inst Canc Sci, Glasgow, Lanark, Scotland

[17] NCRI, Med Oncol, Glasgow, Lanark, Scotland

[18] HCL Ctr Hosp Lyon Sud, Lyon, France

[19] GINECO, Dept Med Oncol, Lyon, France

[20] Reina Sofia Univ Hosp, Cordoba, Spain

[21] GEICO, Dept Med Oncol, Cordoba, Spain

[22] IRCCS Azienda Osped Univ Bologna, Bologna, Italy

[23] MITO, Med Oncol Unit, Bologna, Italy

[24] Klinikum Johann Wolfgang Goethe Univ, Frankfurt, Germany

[25] AGO, Dept Gynecol & Gynecol Oncol, Frankfurt, Germany

[26] Ctr CARIO HPCA, Plerin, France

[27] GINECO, Med Oncol, Plerin, France

[28] Hosp Univ Vall dHebron, Vall dHebron Inst Oncol VHIO, Vall dHebron Barcelona Hosp Campus, Barcelona, Spain

[29] GEICO, Gynaecol Canc Programme, Barcelona, Spain

[30] Vito Fazzi Hosp, Lecce, Italy

[31] MITO, Med Oncol Unit, Lecce, Italy

[32] AstraZeneca, Stat, Cambridge, England

[33] AstraZeneca, Global Med Affairs, Cambridge, England

[34] Inst Cancerol Ouest, Med Oncol, St Herblain, France

[35] ARCAGY GINECO, Dept Med Oncol, Paris, France

来源：

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2022年 / 32卷

关键词：

D O I：

10.1136/ijgc-2022-igcs.27

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

O025/#522

引用

页码：A15 / A15

页数：1

共 50 条

[31] ENGOT-ov43/KEYLYNK-001: A phase III trial of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCA(sic)-nonmutated advanced epithelial ovarian cancer
Fujiwara, K.
Vergote, I. B.
Sehouli, J.
Salutari, V.
Zola, P.
Madry, R.
Wenham, R. M.
Korach, J.
Pautier, P.
Cibula, D.
Lheureux, S.
Hasegawa, K.
Kim, B-G.
Lai, C-H.
Gonzalez-Martinez, A.
Liu, Q.
Keefe, S. M.
Puglisi, M.
Topuz, S.
ANNALS OF ONCOLOGY, 2019, 30
[32] Final overall survival (OS) results from the phase III PAOLA-1/ENGOT-ov25 trial evaluating maintenance olaparib (ola) plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC)
Ray-Coquard, I. L.
Leary, A.
Pignata, S.
Cropet, C.
Gonzalez Martin, A. J.
Bogner, G.
Yoshida, H.
Vergote, I. B.
Colombo, N.
Maenpaa, J.
Selle, F.
Schmalfeldt, B.
Scambia, G.
Guerra Alia, E. M.
Lefeuvre-Plesse, C.
Belau, A.
Lortholary, A.
Gropp-Meier, M.
Pujade-Lauraine, E.
Harter, P.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S1396 - S1397
[33] Final overall survival (OS) results from the phase III PAOLA1/ENGOT-ov25 trial evaluating maintenance olaparib (ola) plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC)
Nagao, S.
Harter, P.
Leary, A.
Cropet, C.
Pignata, S.
Fujiwara, K.
Gonzalez Martin, A. J.
Bogner, G.
Vergote, I.
Colombo, N.
Maenpaa, J.
Selle, F.
Schmalfeldt, B.
Scambia, G.
Guerra Alia, E. M.
Lefeuvre-Plesse, C.
Belau, A.
Lortholary, A.
Gropp-Meier, M.
Pujade-Lauraine, E.
Ray-Coquard, I.
ANNALS OF ONCOLOGY, 2022, 33 : S1503 - S1504
[34] Time without symptoms or toxicity (TWiST) in patients with newly diagnosed advanced ovarian cancer receiving maintenance olaparib or placebo plus bevacizumab: Analysis of PAOLA-1/ENGOT-ov25 phase III trial.
Joly, Florence
Chabaud, Sylvie
Cropet, Claire
Anota, Amelie
Demarchi, Martin
Atasevan, Beyhan
Pisano, Carmen
Lainez, Nuria
Tsibulak, Irina
Yonemori, Kan
Vergote, Ignace
Lapresa, Maria
Mirza, Mansoor Raza
Guillemet, Cecile
Burges, Alexander
Scambia, Giovanni
Izquierdo, Eugenia Ortega
Pujade-Lauraine, Eric
Kurtz, Jean Emmanuel
Ray-Coquard, Isabelle Laure
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[35] Efficacy of subsequent therapies in patients (pts) with advanced ovarian cancer (AOC) in the phase III PAOLA-1/ENGOT-ov25 trial according to whether disease progression occurred during or after the end of olaparib (ola) maintenance
Harter, Philipp
Mouret-Reynier, Marie-Ange
Lorusso, Domenica
Cropet, Claire
Guerra, Eva M.
Wolfrum-Ristau, Pia
Matsumoto, Takashi
Vergote, Ignace
Colombo, Nicoletta
Maenpaa, Johanna Unelma
Lebreton, Coriolan
de Gregorio, Nikolaus
Mosconi, Anna Maria
Rubio-Perez, Maria Jesus
Bourgeois, Hugues
Fasching, Peter A.
Hardy-Bessard, Anne-Claire
Denschlag, Dominik
Pujade-Lauraine, Eric
Ray-Coquard, Isabelle Laure
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[36] Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: Main analysis of second progression-free survival in the phase III PAOLA-1/ENGOT-ov25 trial
Gonzalez-Martin, Antonio
Desauw, Christophe
Heitz, Florian
Cropet, Claire
Gargiulo, Piera
Berger, Regina
Ochi, Hiroyuki
Vergote, Ignace
Colombo, Nicoletta
Mirza, Mansoor R.
Tazi, Youssef
Canzler, Ulrich
Zamagni, Claudio
Guerra-Alia, Eva M.
Levache, Charles B.
Marme, Frederik
Bazan, Fernando
de Gregorio, Nikolaus
Dohollou, Nadine
Fasching, Peter A.
Scambia, Giovanni
Rubio-Perez, Maria J.
Milenkova, Tsveta
Costan, Cristina
Pautier, Patricia
Ray-Coquard, Isabelle
EUROPEAN JOURNAL OF CANCER, 2022, 174 : 221 - 231
[37] A randomized, double-blind phase 3 trial of maintenance therapy with niraparib vs placebo in patients with platinum-sensitive recurrent ovarian cancer (ENGOT-OV16/NOVA trial)
Mirza, M. R.
Monk, B. J.
Oza, A.
Mahner, S.
Redondo, A.
Fabbro, M.
Ledermann, J.
Lorusso, D.
Vergote, I. B.
Rosengarten, O.
Berek, J.
Herrstedt, J.
Tinker, A. V.
Dubois, A.
Gonzalez Martin, A.
Follana, P.
Benigno, B.
Rimel, B. J.
Agarwal, S.
Matulonis, U.
ANNALS OF ONCOLOGY, 2016, 27
[38] A Randomized, Double-Blind Phase 3 Trial of Maintenance Therapy With Niraparib vs Placebo in Patients With Platinum-Sensitive Recurrent Ovarian Cancer (ENGOT-OV16/NOVA Trial)
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2016, 14 (12) : 3 - 5
[39] Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial
Oza, Amit M.
Matulonis, Ursula A.
Malander, Susanne
Hudgens, Stacie
Sehouli, Jalid
del Campo, Josep M.
Berton-Rigaud, Dominique
Banerjee, Susana
Scambia, Giovanni
Berek, Jonathan S.
Lund, Bente
Tinker, Anna V.
Hilpert, Felix
Palacio Vazquez, Isabel
D'Hondt, Veronique
Benigno, Benedict
Provencher, Diane
Buscema, Joseph
Agarwal, Shefali
Mirza, Mansoor R.
LANCET ONCOLOGY, 2018, 19 (08): : 1117 - 1125
[40] Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial
Lorusso, Domenica
Mouret-Reynier, Marie-Ange
Harter, Philipp
Cropet, Claire
Caballero, Cristina
Wolfrum-Ristau, Pia
Satoh, Toyomi
Vergote, Ignace
Parma, Gabriella
Nottrup, Trine J.
Lebreton, Coriolan
Fasching, Peter A.
Pisano, Carmela
Manso, Luis
Bourgeois, Hugues
Runnebaum, Ingo
Zamagni, Claudio
Hardy-Bessard, Anne-Claire
Schnelzer, Andreas
Fabbro, Michel
Schmalfeldt, Barbara
Berton, Dominique
Belau, Antje
Lotz, Jean-Pierre
Gropp-Meier, Martina
Gladieff, Laurence
Lueck, Hans-Joachim
Abadie-Lacourtoisie, Sophie
Pujade-Lauraine, Eric
Ray-Coquard, Isabelle
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (04) : 550 - 558

← 1 2 3 4 5 →